OB/GYN Clinical Alert – August 1, 2025

Intrauterine Hemorrhage-Control Devices for Postpartum Hemorrhage

This multicenter, prospective, observational study comparing intrauterine balloon tamponade vs. vacuum-induced devices for postpartum hemorrhage demonstrated no difference in blood loss after device placement (median quantitative blood loss, 194 mL balloon vs. 240 mL vacuum; P = 0.40), need for blood transfusion (59.7% balloon vs. 50.0% vacuum; P = 0.08), need for more than three units of packed red blood cells (27.0% balloon vs. 24.9% vacuum; P = 0.53), or device failure (7.7% balloon vs. 8.5% vacuum; P = 0.70).

What Are Period Pills?

In this national survey of almost 7,000 people aged 15 to 49 years who were assigned female sex at birth, conducted between December 2021 and January 2022, one-quarter of participants (24%; 95% confidence interval [CI], 22%, 25%) stated that they would personally use period pills and about half of the respondents (52%; 95% CI, 50%, 53%) were in favor of the availability of period pills.

Can Hyperemesis Gravidarum Be Prevented with Metformin?

Although differences were not statistically significant, women with pre-conceptional metformin exposure appeared to have lower rates of hyperemesis gravidarum and comparable nausea and vomiting symptom severity, suggesting a potential protective effect that warrants further investigation in larger, adequately powered studies.

Gepotidacin Tablets (Blujepa)

The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections. It is the first new class of oral antibiotics approved in nearly 30 years.